Japan's drug regulator, the Pharmaceuticals and Medical Devices Agency (PMDA), is planning to open an office in India in a move that may help Indian generics makers gain a larger foothold in Japan. Japan currently worries about its healthcare costs due to its rapidly aging population, according to a story in the Economic Times of India. Indian generics makers have been trying to raise their profile in Japan because the pharma market is second only to the U.S. and worth $110 billion. Japan is trying to lower healthcare costs by increasing its reliance on these generic medicines. Report